Febuxostat: a new agent for lowering serum urate.


Journal Article (Review)

The prevalence of gout has been increasing in epidemic proportions over the last several decades. Hyperuricemia has been shown to be associated with metabolic syndrome and to be an independent risk factor for cardiovascular disease. Associations between hyperuricemia, obesity and aging have provided an impetus in recent years to develop alternative methods of treating hyperuricemia and gout. Febuxostat is a new non-purine xanthine oxidase inhibitor indicated for chronic gout. Febuxostat has been shown to quickly and effectively lower serum urate levels in patients with chronic gout. This manuscript will review febuxostat, its pharmacokinetics and pharmacodynamics, efficacy and adverse events and use in patients with comorbid conditions. The review will also summarize the phase III trials leading up to the drug's approval by both the European Commission in 2008 and the U.S. FDA in 2009. Possible implications the medication may have in the future on gout and hyperuricemia will also be discussed.

Full Text

Duke Authors

Cited Authors

  • Keenan, RT; Pillinger, MH

Published Date

  • April 2009

Published In

Volume / Issue

  • 45 / 4

Start / End Page

  • 247 - 260

PubMed ID

  • 19499090

Pubmed Central ID

  • 19499090

International Standard Serial Number (ISSN)

  • 1699-3993

Digital Object Identifier (DOI)

  • 10.1358/dot.2009.45.4.1354217


  • eng

Conference Location

  • Spain